Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Aligos Therapeutics (ALGS) Return on Capital Employed (2021 - 2025)

Aligos Therapeutics (ALGS) has disclosed Return on Capital Employed for 5 consecutive years, with 0.06% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Capital Employed rose 149.0% year-over-year to 0.06%, compared with a TTM value of 0.06% through Dec 2025, up 149.0%, and an annual FY2025 reading of 0.09%, up 91.0% over the prior year.
  • Return on Capital Employed was 0.06% for Q4 2025 at Aligos Therapeutics, up from 0.87% in the prior quarter.
  • Across five years, Return on Capital Employed topped out at 0.06% in Q4 2025 and bottomed at 1.55% in Q4 2024.
  • Average Return on Capital Employed over 5 years is 0.86%, with a median of 0.81% recorded in 2023.
  • The sharpest move saw Return on Capital Employed crashed -62bps in 2024, then surged 149bps in 2025.
  • Year by year, Return on Capital Employed stood at 0.61% in 2021, then plummeted by -31bps to 0.8% in 2022, then decreased by -16bps to 0.93% in 2023, then crashed by -67bps to 1.55% in 2024, then skyrocketed by 96bps to 0.06% in 2025.
  • Business Quant data shows Return on Capital Employed for ALGS at 0.06% in Q4 2025, 0.87% in Q3 2025, and 0.64% in Q2 2025.